西利宾胺预防抗结核药所致肝损害的临床观察  

Clinical observation of Silymarin in the prevention of hepatic lesion induced by antituberculotic

作　　者：王玉彬[1] 

机构地区：[1]廊坊市疾病预防控控制中心,河北廊坊065000

出　　处：《临床肺科杂志》2012年第1期87-88,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨西利宾胺预防抗结核药引起肝损害的疗效。方法在我所接受抗结核治疗的患者486人,分为观察组,238例,对照组248例,两组均给予2RHZE/4RH方案抗结核治疗,观察组同时加服西利宾胺治疗,对照组加服肌苷治疗。结果观察组发生肝损害21例(21/238)占8.8%,对照组发生肝损害64例(64/248)占25.8%两组比较P<0.05。结论西利宾胺能较好预防治疗抗结核药引起的肝损害。Objective To explore the therapeutic effect of Silymarin in the prevention of hepatic lesion induced by antituberculotic. Method 486 patients which received anti -TB treaetment were randomly divided into the observation group（238 cases） and the control group（248 cases）. The two groups all received anti -TB treaetment of 2RHZE/4RH, meanwhile the observation group plus Silymarin and the control plus inosine. Result 21 cases with hepatic lesion in the observation group（21/238, 8.8% ）, 64 cases with hepatic lesion in the control group（64/248, 18% ） , and there was significant difference compared with two groups（ P 〈0. 05 ）. Conclusion Silymarin can prevent from hepatic lesion induced by antituberculotie, which is worthy of being recommended in clinical practice.

关 键 词：西利宾胺 抗结核药 肝损害 预防 

分 类 号：R595.3[医药卫生—内科学]